-
Circular RNA Vaccines: Innovation, Evidence, and Limits
2026-09-22
The reference review presents circular RNA as a potentially more stable, nonintegrating platform for antigen expression, emphasizing its covalently closed structure, internal ribosome entry sites, and emerging applications in infectious disease and cancer. It also shows that production, purification, delivery, and clinical validation remain unresolved, making circRNA a promising but still early-stage technology.
-
Lamotrigine in BBB and Sodium Channel Research
2026-09-22
Use Lamotrigine as a practical probe for sodium channel signaling, serotonin pathway assays, and high-throughput blood-brain barrier workflows. This guide connects compound preparation and Transwell transport testing with lysosomal-trapping controls, cardiac follow-up assays, and troubleshooting decisions.
-
EZ Cap™ Mouse IL-7 mRNA for APOL1 Studies
2026-09-21
Explore how EZ Cap™ Mouse IL-7 mRNA (m1Ψ, HA tag) can serve as a controlled, transient input in APOL1 cell-injury studies. This article translates a 2025 APOL1 evolution, isoform, and APOL3 paper into assay-design decisions while separating evidence from hypothesis.
-
LDH Cytotoxicity Assay Kit: Practical Workflow
2026-09-21
The LDH Cytotoxicity Assay Kit provides a non-radioactive approach to cell cytotoxicity measurement by detecting LDH released after loss of plasma-membrane integrity. It is useful for comparative cell damage quantification, but LDH release alone should not be used to assign a specific death pathway or replace controls for compound, medium, and optical interference.
-
APOL1 Evolution, Isoforms, and APOL3 Interaction
2026-09-20
The 2025 review by Khalaila and Skorecki integrates APOL1 molecular evolution, splice-isoform biology, and APOL3 interaction data to refine explanations for variant-associated cellular injury. Its main practical implication is that APOL1 renal toxicity should be studied as a context-dependent property shaped by haplotype, isoform, and protein–protein interaction rather than by risk alleles alone.
-
SB 431542: Precision ALK5 Inhibitor Workflows
2026-09-19
Use SB 431542 to separate ALK5-dependent TGF-β signaling from cell-state and immune-cell effects in primary and transformed models. This workflow translates a primary HLA-G+ extravillous trophoblast platform into practical pathway-validation, co-culture, and troubleshooting strategies.
-
Pseudo-UTP: From IVT to Functional RNA
2026-09-18
Pseudo-UTP can improve the performance profile of RNA produced by in vitro transcription, but its value is best judged through a linked chain of biochemical, cellular, and formulation assays. This article presents a decision framework connecting pseudouridine chemistry with mRNA vaccine development, gene therapy RNA modification, and emerging LNP-enabled immunotherapy.
-
N1-Methylpseudouridine and Translation Fidelity
2026-09-18
The reference study shows that N1-methylpseudouridine, the modified nucleoside used in COVID-19 mRNA vaccines, does not substantially disrupt ribosomal decoding or increase miscoded peptides. Its combined translation, RNA-structure, and reverse-transcription experiments distinguish improved RNA performance from translational accuracy, providing a useful framework for mRNA vaccine development and RNA translation mechanism research.
-
CTOP (B5135) for μ-Opioid Receptor Studies
2026-09-17
Learn how CTOP (SKU B5135) can strengthen μ-opioid receptor experiments by separating receptor-dependent signaling from viability or cytotoxicity readouts. This scenario-based guide covers experimental controls, peptide handling, data interpretation, and practical supplier selection.
-
Dimethyloxalylglycine (DMOG) Protocol Guide
2026-09-17
Dimethyloxalylglycine (DMOG), SKU A4506, is a cell-permeable competitive PHD inhibitor for hypoxia-inducible factor stabilization in controlled research workflows. This guide covers concentration selection, solubility, storage, controls, and QC; it is not a diagnostic, therapeutic, or clinical protocol, and no directly matched paper evidence is available for this product entry.
-
TCAIM, OGDH, and Mitochondrial Metabolism
2026-09-16
A 2025 Molecular Cell study identifies TCAIM as a mitochondrial DNAJC co-chaperone that selectively binds OGDH and lowers its abundance through HSPA9 and LONP1. The work establishes a noncanonical proteostasis mechanism for regulating OGDH complex activity and mitochondrial carbohydrate metabolism in cells and mice.
-
CTOP for μ-Opioid Receptor Research
2026-09-16
CTOP provides a reversible pharmacological way to test whether μ-opioid receptor activity drives opioid signaling, mechanical hypersensitivity, or analgesic tolerance. This workflow connects receptor assays with the brain-to-spinal circuit findings reported in recent pain research while emphasizing controls, handling, and interpretation.
-
CTOP: Mapping μ-Opioid Pain Signaling
2026-09-15
CTOP is a selective μ-opioid receptor antagonist for dissecting receptor-dependent signaling in pain models. This article explains how to use CTOP as a causal assay variable when investigating the brain-to-spinal mechanisms of opioid-induced mechanical hypersensitivity and tolerance.
-
CTOP for μ-Opioid Receptor Research
2026-09-15
CTOP provides a selective pharmacological checkpoint for separating μ-opioid receptor-dependent effects from downstream circuit activity in binding, signaling, and pain assays. This workflow-oriented guide shows how to prepare, apply, and troubleshoot CTOP when investigating mechanical hypersensitivity, opioid tolerance, and brain-to-spinal pain mechanisms.
-
Indazole/Indole Glucagon Receptor Antagonists
2026-09-14
The reference study describes a medicinal chemistry series that replaces the pyrazole-centered architecture of MK-0893 with indazole, indole, and related azaindole scaffolds. Structure–activity relationship studies produced potent glucagon receptor antagonists, including GRA 16d, which reduced glucagon-driven glucose excursions in humanized-receptor mouse models after oral dosing.